The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) hosted at the University of Cambridge, with funding from The Mark Foundation for Cancer Research and the Cancer Research UK Cambridge Centre, aims to revolutionise cancer care by re-inventing the treatment pathway for patients.
You can find a full list of media coverage about MFICM on the News page
The Global Ovarian Cancer Research Consortium has awarded its inaugural AI Accelerator Grant to an international team of researchers from Cambridge, Canada, Australia and the United States.
The Cambridge Festival cancer zone will take place on Saturday 21st March 2026, 11:00 – 16:00 in the CAST building on the Biomedical Campus.
Tuesday 24 February 2026, 12-1pm at the Jeffrey Cheah Biomedical Centre (Main Lecture Theatre), University of Cambridge
The Cancer Molecular Diagnostics Laboratory (CMDL) has been awarded ISO 15189 accreditation
The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by affecting patients along their treatment pathway.
